BioMarin Pharmaceutical Inc
SWB:BM8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BioMarin Pharmaceutical Inc
SWB:BM8
|
US |
|
Scully Royalty Ltd
F:MB01
|
CN |
|
RCI Hospitality Holdings Inc
NASDAQ:RICK
|
US |
|
B
|
Boeing Co
DUS:BCO
|
US |
|
Glenveagh Properties PLC
F:GVR
|
IE |
|
Eurasia Fonciere Investissements SA
PAR:EFI
|
FR |
|
N
|
Nova Pacific Metals Corp
CNSX:NVPC
|
CA |
|
Norsk Titanium AS
F:84F
|
NO |
|
Fathom Holdings Inc
NASDAQ:FTHM
|
US |
Intrinsic Value
Is BM8 undervalued or overvalued?
See the intrinsic value estimate for 
BioMarin Pharmaceutical Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What BioMarin Pharmaceutical Does
BioMarin Pharmaceutical makes prescription medicines for rare genetic diseases, especially conditions that affect children and often need lifelong treatment. Its products include enzyme replacement therapies, biologic drugs, and gene therapies designed to treat the underlying cause of certain inherited disorders rather than just easing symptoms.
- Headquarters
- United States of America US
- Employees
- 3 221
- IPO date
- Jul 23, 1999
BioMarin Pharmaceutical has a narrow economic moat
Patents and rare-disease approval protections make it harder for rivals to copy some of BioMarin’s medicines, helping it keep customers in patient groups with few approved treatment options. The protection varies by medicine, and some products already face alternatives.
Read the full moat analysis
Revenue & Expenses Breakdown
BioMarin Pharmaceutical Inc
Earnings Waterfall
BioMarin Pharmaceutical Inc
The intrinsic value for BioMarin Pharmaceutical Inc (BM8) under the Base Case is hidden EUR.
Compared with the current market price of 49.99 EUR, the stock appears hidden.